PMID- 34121583
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211020
IS  - 1369-1627 (Electronic)
IS  - 0954-0261 (Linking)
VI  - 33
IP  - 3
DP  - 2021 May
TI  - Psilocybin and MDMA for the treatment of trauma-related psychopathology.
PG  - 229-249
LID - 10.1080/09540261.2021.1919062 [doi]
AB  - This review examines the role of trauma in psychiatric morbidity and analogous 
      psychoneurobiological changes. Trauma is a necessary criterion for Post-Traumatic 
      Stress Disorder (PTSD), however, trauma history is highly correlated with a 
      variety of psychiatric conditions. Some evidence suggests that Major Depressive 
      Disorder (MDD) is the most common psychiatric condition that arises following 
      trauma. Approximately 50% of PTSD cases present with co-morbid MDD. Overlapping 
      symptomatology and neurobiology between these conditions underlie the debate over 
      whether these phenomena result from problematic nosology or whether comorbid 
      MDD + PTSD is a distinct phenotype of trauma-related psychopathology. Regardless, 
      similar treatment approaches have been employed historically, with varying 
      success. The drug-assisted psychotherapy treatment model, which combines 
      pharmacological and psychotherapeutic approaches, is currently being trialled as 
      a novel treatment approach in psychiatry. Both psilocybin- and 
      3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy have received 
      Food and Drug Administration 'breakthrough therapy' designation for the treatment 
      of resistant MDD and PTSD, respectively. This paper reviews the therapeutic 
      rationale of both psilocybin and MDMA for treating both trauma-related MDD and 
      PTSD.
FAU - Bird, Catherine I V
AU  - Bird CIV
AUID- ORCID: 0000-0002-8656-6931
AD  - The Institute of Psychiatry, Psychology and Neuroscience, King's College London, 
      London, UK.
FAU - Modlin, Nadav L
AU  - Modlin NL
AD  - The Institute of Psychiatry, Psychology and Neuroscience, King's College London, 
      London, UK.
FAU - Rucker, James J H
AU  - Rucker JJH
AD  - The Institute of Psychiatry, Psychology and Neuroscience, King's College London, 
      London, UK.
AD  - South London and Maudsley NHS Foundation Trust, London, UK.
LA  - eng
GR  - CS-2017-17-007/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210614
PL  - England
TA  - Int Rev Psychiatry
JT  - International review of psychiatry (Abingdon, England)
JID - 8918131
RN  - 2RV7212BP0 (Psilocybin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Depressive Disorder, Major/complications/drug therapy
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*therapeutic use
MH  - Psilocybin/*therapeutic use
MH  - Stress Disorders, Post-Traumatic/complications/*drug therapy/*psychology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - MDMA
OT  - Psilocybin
OT  - depression
OT  - drug-assisted psychotherapy
OT  - posttraumatic stress disorder
OT  - psychiatry
OT  - trauma
EDAT- 2021/06/15 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/06/14 09:16
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/06/14 09:16 [entrez]
AID - 10.1080/09540261.2021.1919062 [doi]
PST - ppublish
SO  - Int Rev Psychiatry. 2021 May;33(3):229-249. doi: 10.1080/09540261.2021.1919062. 
      Epub 2021 Jun 14.